These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
    Author: Martínez Jabaloyas JM, Sanz Chinesta S, Jiménez Cruz JF, Flores Corral N, Unda Urzaiz M, Leiva Galvis O, González Romojaro V, Hernández Fernández C, Lledó García E, Rioja Sanz LA, Gonzalvo Ibarra A, Camacho González JE, Ruíz Alvárez-Cienfuegos F, Resel Estévez L, Corral Saleta J, Burgos Rodríguez R, Del Rosal Samaniego JM.
    Journal: Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209.
    Abstract:
    Prospective, randomized, multicenter study in 267 patients with complicated urinary infection from 9 hospitals nationwide. Drug treatment was either Ceftriaxone 1 g once daily parenterally or Cefotaxime parenteral 1 g 8 hourly for a minimum of 7 days. Patients were clinically, analytically and microbiologically evaluated before and after treatment to assess the efficacy and tolerance of both drug products. To evaluate treatment cost, we used the price of both drugs and the material required for their administration (syringe and disposable needle). 119 patients were excluded from the cost-efficacy evaluation and 148 remained in the study (75 assigned to treatment with Ceftriaxone and 73 to Cefotaxime). Clinical efficacy of treatment was 93% and 87.6% for Ceftriaxone and Cefotaxime respectively (p > 0.05). Cost per patient was 27,347 pesetas for Ceftriaxone and 34,490 for Cefotaxime (p < 0.05).
    [Abstract] [Full Text] [Related] [New Search]